





















Wild Poliovirus*, 15 Apr 2002 to 14 Apr 2003
Data in WHO HQ as of 15 April 2003.
*Excludes viruses detected from environmental
surveillance and vaccine derived polio viruses.
The boundaries and names shown and the designations used on this map do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization concerning 
the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.  Dotted lines on maps represent approximate border 
lines for which there may not yet be full agreement. 
© WHO 2003. All rights reserved
Endemic countries
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Wild virus type 3
Importation
Wild virus type 1 and 3
Under investigation
Wild Poliovirus*, 13 Jul 2004 to 12 Jul 2005
*Excludes viruses detected from environmental
surveillance and vaccine derived polio viruses.
The boundaries and names shown and the designations used on this map do not imply the 
expression of any opinion whatsoever on the part of the World Health Organization concerning 
the legal status of any country, territory, city or area or of its authorities, or concerning the 
delimitation of its frontiers or boundaries.  Dotted lines on maps represent approximate border 
lines for which there may not yet be full agreement. 
© WHO 2005. All rights reserved
Case or outbreak following importation
Endemic countries
Wild virus type 1
Wild virus type 3
Wild virus type 1 & 3
Re-established transmission countries



































Relationship Between Sabin 1-Derived Isolates from Haiti































































































































n/a No Indefinite Follow current 
policy
2011 No Indefinite 3 doses 
(Combo)













































































Serotype Strain Source Year Origin Case
1 Mahoney Stool 1941 USA Healthy
2 MEF-1 CNS 1942 Middle East Paralytic
3 Saukett Stool 1950 USA Paralytic
Some issues
1. Assays.
2. Efficacy.
3. Yields and production.
4. Clinical trials. 
5. Combination vaccines and interactions.
6. CONTAINMENT.
Developing country production
Interest by a number of vaccine manufacturers in the developing world to produce 
sIPV.
Large countries seem to be especially interested in producing sIPV, including China, 
India and others.
To produce sIPV safely, prospective manufacturer needs to make substantial capital 
and human resource investments to meet not only the GMP but also the containment 
requirements for sIPV.
Production in developing countries could lead to substantial reductions in cost of sIPV 
production.
WHO/UNICEF Consultation meeting 2007
Prequalification (WHO)
Six functions of the National Regulatory Authority:
• Licensing
• Surveillance of vaccine performance
• Lot release
• Lab access
• GMP inspections
• Clinical evaluation
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Design of mutilated strains
Summary
Polio is very nearly eradicated.
Vaccination will continue for some time, particularly with IPV.
It is unlikely that production will be confined to the existing 
manufacturers.
This has pluses and minuses which might be addressable.
